Mekinist® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Rapid Review
| Commenced | Completed | Outcome |
| 27/11/2015 | 22/12/2015 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 27/07/2016 | 15/03/2017 | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations; April 2018.